EGFR and glioblastoma: However, a randomized phase III trial in newly diagnosed EGFR-amplified glioblastoma found no significant overall survival benefit from adding Depatux-M to standard chemoradiotherapy, and further development of the drug was terminated (Lassman et al., 2023).